Get the Stockscreener App
2.12
3.64%
-0.08
Nls Pharmaceutics Ltd stock is traded at $2.12, with a volume of 52,171.
It is down -3.64% in the last 24 hours and up +9.28% over the past month.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
See More
Previous Close:
$2.20
Open:
$2.15
24h Volume:
52,171
Relative Volume:
0.22
Market Cap:
$7.63M
Revenue:
-
Net Income/Loss:
$-15.47M
P/E Ratio:
-4.24
EPS:
-0.5
Net Cash Flow:
$-13.51M
1W Performance:
-19.39%
1M Performance:
+9.28%
6M Performance:
+16.48%
1Y Performance:
-64.92%
1-Day Range:
$2.11
$2.20
1-Week Range:
$2.03
$2.69
52-Week Range:
$1.30
$6.972
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
Compare NLSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NLSP
Nls Pharmaceutics Ltd
|
2.12 | 10.80M | 0 | -15.47M | -13.51M | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Nls Pharmaceutics Ltd Stock (NLSP) Latest News
Visual analytics tools that track NLS Pharmaceutics AG Equity Warrant performanceTrade Analysis Summary & Safe Capital Growth Tips - Newser
Tick level data insight on NLS Pharmaceutics AG volatilityShort Setup & Verified Swing Trading Watchlists - Newser
Predicting NLS Pharmaceutics AG Equity Warrant trend using moving averagesMarket Weekly Review & Growth Focused Investment Plans - Newser
Key metrics from NLS Pharmaceutics AG Equity Warrant’s quarterly dataNew Guidance & Intraday High Probability Alerts - Newser
Watch for Trend Continuation in NLS Pharmaceutics AG Next Week2025 Market WrapUp & Safe Entry Zone Identification - beatles.ru
Using R and stats models for NLS Pharmaceutics AG forecastingWall Street Watch & Free Community Supported Trade Ideas - Newser
NLS Pharmaceutics AG Equity Warrant’s volatility index tracking explained2025 Technical Overview & Technical Pattern Alert System - Newser
Using Ichimoku Cloud for NLS Pharmaceutics AG technicals2025 Institutional Moves & AI Powered Buy and Sell Recommendations - Newser
Top chart patterns to watch in NLS Pharmaceutics AG Equity WarrantTrade Risk Assessment & Low Volatility Stock Suggestions - Newser
Is NLS Pharmaceutics AG Equity Warrant stock entering bullish territory2025 Year in Review & Real-Time Stock Price Movement Reports - Newser
Comparing NLS Pharmaceutics AG Equity Warrant in custom built stock radarsPortfolio Value Report & Real-Time Market Trend Scan - Newser
Building trade automation scripts for NLS Pharmaceutics AG Equity WarrantMarket Growth Summary & Breakout Confirmation Alerts - Newser
Published on: 2025-08-30 21:36:21 - Newser
Short interest data insights for NLS Pharmaceutics AGEarnings Overview Report & Daily Profit Maximizing Trade Tips - Newser
Using Bollinger Bands to evaluate NLS Pharmaceutics AG Equity WarrantPortfolio Value Summary & Daily Entry Point Alerts - Newser
NLS Pharmaceutics Extends Merger Deadline with Kadimastem to October 31, 2025. - AInvest
NLS Pharmaceutics Extends Merger Agreement with Kadimastem - TipRanks
Detecting support and resistance levels for NLS Pharmaceutics AGInsider Selling & Technical Entry and Exit Tips - Newser
Is NLS Pharmaceutics AG Equity Warrant a candidate for recovery playTrade Exit Summary & Safe Capital Growth Tips - Newser
Published on: 2025-08-29 16:48:48 - Newser
Best data tools to analyze NLS Pharmaceutics AG stockTrade Analysis Report & Daily Volume Surge Signals - Newser
Is this a good reentry point in NLS Pharmaceutics AG Equity WarrantWeekly Risk Report & Trade Opportunity Analysis Reports - Newser
Risk vs reward if holding onto NLS Pharmaceutics AGQuarterly Market Summary & Expert Approved Momentum Ideas - Newser
Price momentum metrics for NLS Pharmaceutics AG Equity Warrant explained - Newser
Price action breakdown for NLS Pharmaceutics AG Equity WarrantPortfolio Risk Report & Fast Exit Strategy with Risk Control - Newser
Can NLS Pharmaceutics AG reach all time highs this yearQuarterly Growth Report & Safe Entry Zone Identification - sundaytimes.kr
Real time pattern detection on NLS Pharmaceutics AG stockJuly 2025 Highlights & Technical Entry and Exit Alerts - Newser
Analyzing drawdowns of NLS Pharmaceutics AG Equity Warrant with statistical tools2025 Top Decliners & AI Driven Price Predictions - Newser
Understanding NLS Pharmaceutics AG’s price movementMarket Sentiment Report & Real-Time Volume Analysis - Newser
Nls Pharmaceutics Ltd Stock (NLSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):